Eppendorf striving to ensure all labs are smart, safe, and stress-free, with Eppendorf Advantage
![](/46/pdcnewsitem/04/26/32/EPP_117a_Image.jpg)
A range of best-in-class solutions that drive productivity in the laboratory.
Eppendorf has announced the latest Advantage promotion period, until 31 December 2016, on a range of best-in-class solutions that drive productivity in the laboratory. With sample safety, intuitive functionality, and reliability in mind, Eppendorf offers solutions that support a smart, safe, and stress-free environment for researchers across the life sciences industry.
For many research labs, handling hazardous liquids, such as foaming, viscous, volatile, dense, corrosive or hazardous solutions, can be challenging, particularly when the properties of these liquids can affect, and impair, the accuracy and reproducibility of results. The Advantage range includes, the ergonomically designed Multipette M4, with positive displacement, and Combitips advanced, which can eliminate these associated challenges. The Multipette M4 offers a unique volume range, 1 µL–10 µL, and can accommodate 9 Combitips advanced sizes from 0.1 to 50 mL. In addition, automatic Combitip recognition, combined with the ability to conduct 100 dispensing steps, without the need for refilling the tip, ensures fast, precise, and contamination-free dispensing.
Steve Dey, Marketing Director, Eppendorf UK Limited commented: “We at Eppendorf are always striving to be the expert partner in life science laboratories. As one of the industry's technology leaders, we have set industry standards time and again over past decades and always look to the future to contribute to making repetitive laboratory workflows simple, precise, safe and efficient. Eppendorf Advantage is an opportunity for those working across life sciences to optimise their laboratory productivity.”
Additional solutions for researchers and technicians to take advantage of include the Eppendorf ThermoMixer C; with quick and easy-to-exchange SmartBlocks for common lab vessel and plate formats from 5 µL to 50 µL, it is ideally suited to applications such as plasmid/RNA/DNA purification, cDNA synthesis, bacterial growth and lysis reactions at 100 °C. Researchers can expect consistently dependable and reproducible assay results due to outstanding mixing performance, with 2DMix-Control, and exceptional temperature regulation, meaning samples can be simultaneously mixed and incubated.
Until 31 December, the 24-place Centrifuge 5424, and refrigerated 5424 R, will also be on offer, as part of a Special Value Pack which also includes an 18-place Eppendorf Kit rotor, giving researchers access to state-of-the-art cooling technology, for maximum sample protection. Similarly, researchers can purchase the Innova 44, and 44R incubator shakers, which offer broad temperature capabilities and varying shaking speeds for culturing a wide variety of cell types in flasks up to 5 L.
Researchers and technicians will also be able to purchase the perfect tools for methods in nucleic acids, protein, and turbidity measurements: the Eppendorf BioPhotometer D30 records at fixed wavelengths, clearly processes data volume, and makes evaluating results fast, and simple, whilst the Eppendorf µCuvette G1.0 is ideal for microvolume measurements of highly concentrated samples without prior dilution.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance